Department of Medical Biochemistry, College of Medicine, University of Sulaimani, Sulaimaniyah, Iraq.
Department of Medicine, College of Medicine, University of Sulaimani, Sulaimaniyah, Iraq.
J Int Med Res. 2022 Jul;50(7):3000605221110493. doi: 10.1177/03000605221110493.
The role of ABO types and RhD antigen in coronavirus disease 2019 (COVID-19) severity has been investigated in several recent studies. Thus, the objective of this study was to identify the relationship of ABO and RhD types with symptomatic COVID-19 disease and determine the groups associated with an increased risk of hospitalization.
This observational case-control study was performed in 530 Iraqi-Kurdish patients with COVID-19. Among them, 184 were severe cases that required hospitalization, while 346 were mild to moderate cases that were treated at home. ABO and RhD antigen groups were compared between cases and 1698 control records from 1 year before the pandemic. The diagnosis of COVID-19 was based on real-time polymerase chain reaction tests and high-resolution chest computed tomography scans with the typical clinical presentation.
There were no significant differences in ABO and RhD antigen distributions between the COVID-19 cases and non-COVID controls. No ABO group was associated with the risk of hospitalization as a marker of the severity of infection.
There was no significant association between symptomatic COVID-19 disease and any ABO group or RhD antigen type. No impact of ABO groups on hospitalization was documented.
在最近的几项研究中，已经研究了 ABO 血型和 RhD 抗原在 2019 年冠状病毒病（COVID-19）严重程度中的作用。因此，本研究的目的是确定 ABO 和 RhD 血型与有症状的 COVID-19 疾病之间的关系，并确定与住院风险增加相关的群体。
这是一项在 530 名患有 COVID-19 的伊拉克库尔德患者中进行的观察性病例对照研究。其中，184 例为需要住院治疗的重症病例，346 例为在家中接受治疗的轻症至中度病例。在病例组和大流行前 1 年的 1698 例对照记录中比较了 ABO 和 RhD 抗原组。COVID-19 的诊断基于实时聚合酶链反应测试和具有典型临床表现的高分辨率胸部计算机断层扫描。
COVID-19 病例与非 COVID 对照之间的 ABO 和 RhD 抗原分布无显着差异。没有 ABO 组与感染严重程度的住院风险相关。
有症状的 COVID-19 疾病与任何 ABO 组或 RhD 抗原类型之间没有显着关联。没有记录到 ABO 组对住院的影响。
